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Abstract
Introduction
Management of persistently non-adherent youth living with HIV (YLHIV) with virologic failure
(VF) on combination antiretroviral therapy (cART) remains challenging. One strategy has
been using 3TC/ FTC monotherapy (3TC/FTC), which in the presence of the M184V resis-
tance mutation, does not suppress viral replication nor select for additional drug resistance
mutations, and reduces viral fitness with limited side effects. P1094 compared the immuno-
logic outcome of continuing failing cART vs. switching to 3TC/FTC as a “bridging strategy”
to subsequent suppressive cART for non-adherent YLHIV with pre-existing M184V
resistance.
Materials & methods
Participants with documented nonadherence, M184V mutation, CD4+ T cell count100
cells/mm3 and VF (HIV-1 plasma RNA400 copies/mL (2.6 log10 HIV-1 RNA) were enrolled
and randomized to continue failing cART vs. switch to 3TC/FTC. The primary endpoint (time
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to30% CD4+ T cell decline or development of CDC class C events) at 28-weeks were
assessed by Kaplan-Meier (K-M) curves in an intent-to-treat analysis.
Results
Thirty-three perinatally acquired YLHIV participants (16 continuing cART and 17 3TC/FTC)
enrolled in the study. The median age, entry CD4+ T cell count, and viral load were 15 years
(Inter-quartile range (IQR) 14–20), 472 cells/mm3 (IQR 384–651), and 4.0 log10HIV-1 RNA
copies/ml (IQR 3.2–4.5), respectively. Five participants, all in the 3TC/FTC arm, reached
the primary endpoint for absolute CD4+ T cell decline (p = 0.02, exact log-rank test compar-
ing monotherapy to cART). The Kaplan-Meier estimate of probability of primary endpoint on
3TC/FTC at 28 weeks was 0.41 (standard error 0.14). There were no CDC class C events or
deaths and no statistically significant difference in frequencies of adverse events between
the arms.
Conclusions
Non-adherent participants randomized to 3TC/FTC were more likely than those maintained
on failing cART to experience a confirmed decline in CD4+ count of30%. Although this
study suffers from limitations of small sample size and premature discontinuation, the ran-
domized comparison to continuing failing cART indicates that 3TC/FTC provides inferior
protection from immunologic deterioration for non-adherent youth with M184V resistance.
Better alternatives to 3TC/FTC such as ART with higher barriers to resistance and novel
adherence and treatment strategies for nonadherent youth are urgently needed.
Trial registration
Clinical Trials.gov NCT01338025
Introduction
Durable virologic suppression using combination antiretroviral therapy (cART) is most reli-
ably achieved for patients with excellent adherence, with small amounts of nonadherence con-
ferring risk of emergent resistance and viral load breakthrough [1, 2]. However, it is estimated
that up to 40% of pediatric and adolescent patients who initiate a new regimen fail on that regi-
men within the first 1–2 years [3–5], primarily due to nonadherence. This suboptimal adher-
ence, with viremia in the presence of continued drug pressure at suboptimal levels, results in
development of resistant quasispecies and viral escape. Nonadherence with resultant viremia
affects 30–40% of children and youth with perinatally acquired HIV infection (PA-HIV) on
cART[6–8], and is likely due to multiple causes (treatment fatigue, pill burden, desire for nor-
malcy, depression, transition of the responsibility of medication administration from the care-
giver to the child) that may function independently or in concert[9].
Antiretroviral management in the setting of poor adherence in children and youth living
with HIV is increasingly challenging for providers. A balance must be struck between the need
to continue cART to maintain immunologic integrity and the desire to simplify the therapeutic
regimen, foster optimal adherence, and minimize development of resistance, while awaiting
for youth to mature and develop better adherence. To improve adherence, multiple strategies
Randomized trial of 3TC/FTC monotherapy in youth
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have been tested (e.g., cell phone reminders, counseling, MEMS caps, G-tube placement,
directly observed therapy, financial incentives), yet no gold standard has emerged [9, 10].
However, during the time providers are working to improve adherence, nonadherence fre-
quently continues with the attendant risk of accumulation of ARV drug resistance and
reduction of future treatment options. The question of what to do with the cART while
working on adherence remains a centrally important one in the management of persistently
nonadherent children and youth living with PA-HIV in need of therapy and there are no
consensus guidelines about how this should be managed. Switching to a new regimen in the
setting of nonadherence, particularly, when nonadherence is unrelated to side effects, may
lead to development of resistance to the new regimen. Discontinuation of cART is generally
avoided in patients who meet treatment criteria, in light of data from the SMART study that
highlights the increased morbidity risk secondary to HIV-related and non-related clinical
events with treatment discontinuation[11]. Bridging strategies, without resistance conse-
quences, could provide time for intensive efforts to improve adherence, which might
improve the chance that these patients would succeed on a subsequent cART regimen. One
such strategy is lamivudine (3TC) or emtricitabine (FTC) monotherapy. The rationale for
this strategy is as follows: 1) 3TC or FTC are components of the nucleoside/nucleotide
reverse transcriptase inhibitor (NRTI) backbone of most first line cART regimens, 2) 3TC
and FTC have minimal side effects, 3) the M184V resistance mutation, resulting in high-
level drug resistance to both 3TC and FTC, develops rapidly in the setting of nonadherence
and is present in many treatment-experienced children and adolescents with PA-HIV [7, 12,
13], 4) the M184V resistant mutation reduces viral fitness, and has been associated with a
reduction in viral load of approximately 0.5 log10 c/mL[14], and 5) it does not confer signifi-
cant cross-resistance to other NRTIs and increases susceptibility of HIV to other antiretrovi-
ral (ARV) drugs [e.g., tenofovir disproxil fumarate (TDF), zidovudine (AZT)][15]. Once the
M184V mutation develops, no additional mutations occur with further use of 3TC or FTC
monotherapy.
This strategy has been shown to be superior to discontinuing all antiretroviral therapy in
adults[16]. Observational experience of PI interruption and continuation of dual-NRTI for
children and youth with persistent viremia due to nonadherence, toxicity, and limited treat-
ment options showed unchanged viremia, but relative safety of NRTI simplification with sus-
tained CD4%>15, although significant declines did occur[17]. At the time the study was
developed, 3TC/FTC monotherapy was listed as a potential option in the U.S. pediatric antire-
troviral treatment guidelines for patients with persistent viremia with NRTI resistance[18];
and was and still is employed in settings where access to second and third line antiretroviral
agents and/or persistent nonadherence has led to limited treatment options[19–22]. The pri-
mary objective of the P1094 study was to compare 3TC/FTC monotherapy to continuing fail-
ing cART in patients with persistent nonadherence.
Materials & methods
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1094 was a
multi-center (domestic and international), open-label, Phase IV randomized, controlled, com-
parative trial to evaluate continuation of non-suppressive cART (Arm A) vs. 3TC/FTC mono-
therapy (Arm B) for 28 weeks (in both arms) (NCT01338025).[23] All of the participating sites
are part of the IMPAACT network of clinical research sites. Participants were (perinatally or
non perinatally) HIV-infected children, adolescents, and young adults8 to<25 years old, on
a non-NNRTI (non-nucleoside reverse transcriptase inhibitor) regimen for at least 6 months,
with documented nonadherence (e.g., self-report or pharmacy report, despite documented
Randomized trial of 3TC/FTC monotherapy in youth
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interventions to improve nonadherence), M184V resistance mutation at or prior to screening
on standard, clinically available genotyping assays, absolute CD4+ T cell count100 cells/
mm3, and VF (defined as HIV-1 plasma RNA400 copies/mL on at least two occasions
including screening at least 2 months after initiating the regimen and within 6 months of
study entry). When slow enrolment was observed, a site survey was conducted and in
response, the following changes were made to the eligibility criteria (March 7 2012): absolute
CD4+ T cell count was lowered from 250 to 100 cells/mm3 and the time demonstrating failure
from 6 months to 2 months.
Main exclusion criteria included hepatitis B infection, active malignancy within the prior
two years, active opportunistic or other infection; 1 CDC class C event within 12 months of
entry, or viral load >250,000 copies/mL at screening. Participants were enrolled between May
2011 and January 2013 and randomized 1:1 to the two treatment groups using a dynamic per-
muted block system with institutional balancing (maximum institutional imbalance of 2),
stratified by CD4+ T cell count (<400 cells/mm3 versus400 cells/mm3). Participants were
enrolled online and randomized at time of enrollment via computer algorithm at the Data
Management Center.
For participants assigned to Arm A, the protocol required that the participant continue
their current ART regimen, which was prescribed and monitored by the participant’s pro-
vider. Participants assigned to the monotherapy arm (Arm B) received either 3TC or FTC
(the choice of 3TC or FTC was left to the provider) and discontinued other ART. Sites were
expected to provide and document adherence support measures (per their standard of care)
during the study. The target sample size of 344 was chosen to provide 80% power to detect a
difference of 0.15 between study arms in proportions of participants with immunologic
deterioration using a log-rank test with a 2-sided Type I error rate of 0.05. Due to poor
accrual, the final sample size was 32 eligible participants. The antiretroviral agents were not
provided by the study. The study was approved by the Institutional review boards (IRBs) of
all participating clinical research sites (CRS) (Bronx-Lebanon CRS, New York, United
States; Chiang Mai University Pediatrics-Obstetrics CRS, Thailand; Children’s National
Med. Ctr. Washington DC NICHD CRS, United States; Duke University Medical Center
CRS, Durham, North Carolina, United States; Hosp. General de Agudos Buenos Aires
Argentina NICHD CRS; Hosp. Geral De Nova Igaucu Brazil NICHD CRS; Inst de Infectolo-
gia Emilio Ribas, Sao Paulo Brazil NICHD CRS; and Johns Hopkins Univ. Baltimore
NICHD CRS, United States. All participating sites received ethics approval prior to study
initiation at their site. Approvals were received from April 13, 2011 to March 7, 2012. Partic-
ipants and their parent/guardian, where relevant, signed written informed consent, which
was documented in the participant’s chart and/or study log as directed by their local IRB
requirements. A data safety monitoring board (DSMB) monitored the study conduct
throughout the study.
Study measurements
Study measurements included lymphocyte subsets at each study visit (0, 4, 12, 20, 28 weeks),
HIV RNA testing (0, 4, 12, 28 weeks), and safety monitoring labs including hematology (0, 4,
12, 20, 28 weeks and chemistries (0, 12, 28 weeks). Plasma and peripheral blood mononuclear
cells (PBMCs) for inflammatory and immune activation markers were collected at 0, 12, and
28 weeks. Self-reported adherence was also assessed at each study visit by collection of 3-day
recall and evaluation of interventions employed to enhance adherence. Batched resistance test-
ing was planned as part of the protocol, however, this was not performed when the study
ended early.
Randomized trial of 3TC/FTC monotherapy in youth
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Immunology assays
Plasma and Ficoll-Hypaque density gradient isolated peripheral blood mononuclear cells
(PBMCs) were cryopreserved within 8 hours of blood draw. Plasma markers of inflammation
and immune activation were determined with ELISA kits, using duplicate samples on the
same plate per subject, for D-Dimer (Imuclone/Sekisui Diagnostics, Lexington, MA),
sVCAM-1 (Millipore, Billerica, MA), and soluble CD4 (sCD14), interleukin-6 (IL-6), and high
sensitivity C-reactive protein (hsCRP) (R&D Systems, Minneapolis, MN). These markers were
selected based on correlation with morbidity and mortality in studies of HIV-1 infected adults
[23–27]. Multi-parameter flow cytometric analysis (LSRII, Becton Dickinson, Franklin Lakes,
NJ; FlowJo Version 9.6.1, Treestar, Ashland, OR) of cryopreserved PBMC stained with
CD3-FITC and CD4-Qdot605 (Invitrogen/Life technologies, Grand Island, NY), CD8-AF700
and HLA-DR-APC (BD Biosciences, San Jose CA), CD38-PE, CD95-Pacific Blue, CD31-PE-
CY7, CD27-APC-CY7, CD45RO-PE-CY5 (Biolegend, San Diego, CA), and LIVE/DEAD Fix-
able Aqua Dead Cell Stain (Invitrogen/Life technologies, Grand Island, NY) was performed.
The percent of naive (CD27+ CD45RO- CD95-) and activated (CD38+ HLA-DR+) cells within
total CD3+/CD4+ and CD3+/CD8+ viable lymphocytes was determined. In addition, the
percentage of recent thymic emigrants (RTE) (CD31+ CD27+ CD45RO- CD95-) among
CD3+/CD4+ lymphocytes was determined[28].
Statistical analysis
The primary endpoint was time to time to immunologic deterioration, defined as first30%
decline in absolute CD4+ T cell count from baseline or development of CDC class C events.
Additional analyses were done on rates of adverse events or deaths, change in viral load,
changed in biomarkers of inflammation and immune activation, and adherence at the end of
follow-up; as well as baseline immune characteristics on the 3TC/FTC monotherapy arm.
Kaplan-Meier curves and log-rank tests were used to compare the treatment arms with
respect to time to immunologic failure.[29] The probability of avoiding immunologic deteri-
oration by 28 weeks was estimated via the method of Kaplan and Meier, and the 95% confi-
dence intervals (CIs) for this probability were computed for each arm. Linear mixed effects
models were used to estimate, in an exploratory manner, rates of change in CD4+ T cell
counts and viral load levels over time for the two arms.[30] Three-day recall of adherence
was categorized as missed doses in the past 3 days (yes/no) at entry and 28 weeks. The pro-
portion of participants at week 28 that were in the different categories of adherence, as mea-
sured by 3-day recall, was compared between the two study arms using Fisher’s exact test.
Lastly, as an exploratory objective, changes in immune activation, inflammatory biomarkers,
and LDL and HDL cholesterol were assessed for participants in the 3TC/FTC arm followed
at domestic sites only, and compared between groups formed by presence or absence of
immunologic deterioration by week 28 using Kruskal-Wallis tests. All analyses were intent-
to-treat and included all eligible participants unless otherwise specified. All tests were done
using SAS 9.4, StatXact.
Results
Enrollment occurred May 10, 2011 through January 16, 2013 and the study was discontinued
in February 2013 due to slow accrual; all participants were off study by May 15, 2013. Thirty-
three participants were enrolled, out of targeted enrollment of 344, of whom one was ineligible
and did not have any post-entry visits (Fig 1). We present the results for the 32 perinatally
HIV-infected participants enrolled prior to study closure (15 randomized to continuing cART
and 17 to 3TC/FTC). While the study was open to both perinatally and non-perinatally HIV-
Randomized trial of 3TC/FTC monotherapy in youth
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infected individuals, only PHIV were enrolled. Participants were from diverse regions (Argen-
tina n = 3, Brazil n = 5, Thailand n = 6, U.S. n = 18). The demographic and clinical characteris-
tics of the participants are presented in Table 1. Participants were median age 15 years (Inter-
quartile range (IQR) 14–20), 68% female, and 52% black. Median entry CD4+ T cell count and
viral load were 472 cells/mm3 (IQR 384–651) and 4.0 log10HIV-1 RNA copies/ml (IQR 3.2–
4.5), respectively. A median of 4 interventions (e.g., counseling, text reminders, directly
observed therapy) had been used to address nonadherence prior to study. The median dura-
tion on study intervention of 27 weeks (IQR 12–34) was not different between the two treat-
ment arms.
Immunologic deterioration
Five participants, all in the 3TC/FTC monotherapy arm, reached the primary endpoint for
decline in CD4+ T cell count (exact log-rank test p = 0.02, Fig 2). The Kaplan-Meier estimate
of probability of immunologic failure at 28 weeks was 0.41 (standard error 0.14). No partici-
pants experienced CDC Class C events.
To test the null hypothesis of identical rates of change in CD4+ T cell counts over time on
study, repeated measures modeling was used. The model (Table 2) included main effects of
time on study and treatment assignment, the product of time on study and treatment assign-
ment, adjustments for patient age and sex, and a random intercept to accommodate between-
patient variability. The coefficient of the product term permits estimation of the interaction
between study week and treatment arm, with participants on the 3TC/FTC arm estimated to
lose 5.31 cells/mm3 per week (p = 0.03) while those on the cART arm were estimated to gain
3.82 cells/mm3 per week (p = 0.10). The median (IQR) change in CD4+ T cell count over the
study period was 44 (-16, 142) for the cART arm and -70 (-329, -18) for the 3TC/FTC arm
(Kruskal-Wallis test, p = 0.004).
Fig 1. CONSORT diagram for P1094.
https://doi.org/10.1371/journal.pone.0178075.g001
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Adverse events, deaths, change in viral load, and adherence
There were no deaths. There was only one grade 3 or higher adverse event reported; one par-
ticipant on the cART arm had a grade 4 total bilirubin, attributable to receiving atazanavir.
There were no significant differences in self-reported adherence between the two arms at base-
line or during the study period. However, compared to baseline, at the end of the study period,
fewer participants in both treatment arms reported missing doses in the prior 3 days, 47% at
baseline vs. 33% at the end in the cART arm and 59% vs. 18% in the 3TC/FTC arm. Partici-
pants in the cART arm had a median decline in viral load of -3.78 (IQR -4.25 to -2.25)
Iog10HIV-1 RNA copies vs. an increase of 3.87 (IQR -3.73 to 4.48) log10HIV-1 RNA copies/ml
in the 3TC/FTC arm (p = 0.08), although the difference was not statistically significant. Four
(67%) of the six participants on cART with viral load data for week 24/28 had decreases in log
viral load of more than 0.5, while none of the six participants on 3TC/FTC did (p = 0.06, Fish-
er’s exact test.)
Immunology and immune activation
Biomarkers of inflammation and immune activation were assessed for participants in the
3TC/FTC arm followed at domestic sites with available samples. Fourteen participants had
Table 1. Baseline characteristics of participants enrolled in P1094.
Treatment
Characteristic cART (N = 15) 3TC/FTC (N = 17) Total (N = 32)
Age at Entry (Years) Median (Q1, Q3) 18 (14, 20) 15 (13, 20) 15.0 (13.5, 20.0)
Min, Max 11, 24 10, 21 10, 24
10–14 5 (33%) 6 (35%) 11 (34%)
15–17 2 (13%) 5 (29%) 7 (22%)
18–24 8 (53%) 6 (35%) 14 (44%)
Sex Male 4 (27%) 7 (41%) 11 (34%)
Female 11 (73%) 10 (59%) 21 (66%)
Race Asian 2 (13%) 3 (18%) 5 (16%)
Black or African American 9 (60%) 8 (47%) 17 (53%)
White 4 (27%) 6 (35%) 10 (31%)
Ethnicity Hispanic or Latino 6 (40%) 8 (47%) 14 (44%)
Not Hispanic or Latino 8 (53%) 9 (53%) 17 (53%)
Unknown 1 (7%) 0 (0%) 1 (3%)
Entry RNA log10(copies/ml) Median (Q1, Q3) 4.2 (3.0, 4.8) 4.0 (3.2, 4.1) 4.0 (3.1, 4.5)
Min, Max 2.2, 5.6 2.2, 4.9 2.2, 5.6
Entry CD4 (cells/mm3) Median (Q1, Q3) 476 (361, 669) 444 (350, 654) 472 (356, 662)
Min, Max 257, 848 160, 1191 160, 1191
# reasons used to determine sub-optimal adherence* Median (Q1, Q3) 3 (2, 3) 2 (2, 3) 3 (2, 3)
Min, Max 1, 6 1, 5 1, 6
# interventions used to address non-adherence? Median (Q1, Q3) 4 (3, 7) 4 (3, 5) 4 (3, 6)
Min, Max 1, 9 1, 9 1, 9
*Nonadherence: admission of incomplete adherence (2+ occasions taking <90% of meds)(78%), persistent viremia without plausible explanation (69%),
agreement of 2 providers (59%), miss and doses in past 3 days (non-adherence questionnaire) (53%), pharmacy refill history (34%), pill counts (22%), drug
levels (6%), other (3%)
?Interventions attempted: counseling (94%), frequent clinic visits (72%), reminders (63%), therapy (44%), peer support (38%), ADL triggers (38%), regimen
modification/simplification (31%), rewards (31%), home visits (22%), direct observation (9%), G-tube (6%), other (9%)
https://doi.org/10.1371/journal.pone.0178075.t001
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biomarker data (sCD14, IL-6, hsCRP, sVCAM-1, and D-dimer) available at both baseline and
Week 24/28 (9 in the 3TC/FTC arm and 5 in the cART arm). There were no significant differ-
ences between arms in the change from baseline for any of the markers (Table 3). As an explor-
atory analysis, baseline immune characteristics were examined among the participants in the
3TC/FTC monotherapy arm to determine whether there were correlations with subsequent
immune deterioration. There were no differences in any of the baseline plasma markers for
those that did (n = 7) or did not (n = 4) have a30% decline in absolute CD4 + T cell count.
There were also no differences in baseline frequency of activated CD4+ or CD8+ T cells nor
the frequency of CD4+ T cells that were naïve or recent thymic emigrants (S1 and S2 Tables).
Given the restricted sample size, only large differences could be detected.
Discussion
To our knowledge, this is the first and only randomized control trial comparing 3TC/FTC
monotherapy to continuing cART in any population of individuals living with HIV. In this
Fig 2. Probability of not experiencing immunologic failure.
https://doi.org/10.1371/journal.pone.0178075.g002
Table 2. Random effects mixed model for CD4 decline.
Treatment 95% Confidence Limits
Effect* Arm Estimate (Lower, Upper) P
Intercept _ 922.5 (495.3, 1349.7) <0.001
Age _ -25.0 (-46.7, -3.3) 0.02
Female _ -3.3 (-171.7, 165.0) 0.97
Week*Treatment 3TC/FTC -5.3 (-9.9, -0.7) 0.03
Week*Treatment HAART 3.8 (-0.7, 8.4) 0.10
*The week by treatment interaction terms represent the rates of change over time for each treatment
https://doi.org/10.1371/journal.pone.0178075.t002
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multi-site study of YLHIV with persistent virologic failure on cART, those who were random-
ized to 3TC/FTC monotherapy were significantly more likely to experience30% decline in
absolute CD4+ T cell count over 28 weeks compared with those maintained on failing cART.
The change from baseline in markers of inflammation and immune activation did not differ
between the two groups. Immune correlates at baseline were not different between those who
did and did not experience immunologic decline in the 3TC/FTC arm, though this was per-
formed on a limited sample size.
A prior study of adults with relatively robust baseline median CD4+ T cell counts of 570
(IQR 466–636) cells/mm3 compared 3TC monotherapy to discontinuation of cART and found
that the monotherapy strategy was superior to cART discontinuation [16]. Specifically, partici-
pants with lower CD4+ T cell counts were more likely to have clinical deterioration than those
at higher CD4+ T cell counts. We were unable to conduct an analysis of higher vs. lower CD4+
T cell counts at entry on clinical deterioration due to both a limited sample size and the major-
ity of our participants having CD4 + T cell counts >350 cells/mm3. Others have shown that
withdrawing the NRTIs as opposed to interrupting PIs or NNRTIs in a failing regimen may
have the greatest impact on immune decline, a different approach than was used in our study
[31].
It is possible that the use of the comparison cART group on PI-based regimens may have
led to the dramatically different outcomes between the two study arms. Opravil et al studied 26
clinically stable, significantly pre-treated adults (median age 43 years; median CD4+ T cell
count of 432 [IQR 378–540] cells/mm3) who were switched in an uncontrolled, one-armed
study from a failing (VL> than 400 copies/mL) cART regimen to 3TC monotherapy[32]. The
proportion of patients reaching the clinical endpoint of a 30% decline in CD4+ T cell count
or a CD4+ T cell count <200 cells/mm3 at 24, 36, and 48 weeks was 36%, 57%, and 70%,
respectively. When the investigators analyzed the participants stratified by the failing regimen
at baseline (PI vs. reverse transcriptase inhibitor (RTI)-based cART (NNRTI or NRTI)), 81%
of participants on PI-based cART vs. 40% of participants on RTI-based cART reached the
clinical endpoint, despite similar baseline CD4+ T cell counts and other characteristics. The
decline in absolute CD4+ T cell was not statistically different between the two groups, how-
ever, patients who were initially on PI-based cART had greater increases in the viral replication
capacity, perhaps due to outgrowth of viral strains lacking PI resistance mutations detected on
resistance testing in the absence of ART pressure. The authors concluded that 3TC monother-
apy may be considered as a short-term strategy for “selected” patients failing RTI-based cART,
Table 3. Immune activation and inflammation biomarker change from baseline to week 24/28.
Biomarker Median change from baseline (IQR) P-value*
cART N = 5 3TC/FTC N = 9
Soluble CD4 (ug/ml) ? 0.1 (-0.9, 0.3) -0.1 (-0.1,0.1) 0.84
Interleukin-6 (pg/ml) ? -1.2 (-2.8, 1.0) -1.7 (-1.7,-.03) 0.74
hsCRP (ng/ml) ? 2.0 (0.5, 2.2) 0.1 (-.03, 0.5) 0.21
sVCAM-1 (ng/ml) ? -40 (-148, 338) -307 (-658, 329) 0.22
D-dimer (ng/ml) ? -146 (-718, 31) -28 (-40,44) 0.26
* Wilcoxon Test
?Plasma biomarkers of immune activation and inflammation determined by ELISA.
IQR, interquartile range; cART, combination antiretroviral treatment; 3TC, lamivudine; FTC, emtricitabine,
hsCRP, high sensitivity C-reactive protein; sVCAM-1, soluble vascular cellular adhesion molecule-type 1; D-
dimer
https://doi.org/10.1371/journal.pone.0178075.t003
Randomized trial of 3TC/FTC monotherapy in youth
PLOS ONE | https://doi.org/10.1371/journal.pone.0178075 June 12, 2017 9 / 14
but not PI-based regimens due to concern for increased viral fitness and greater likelihood of
CD4+ T cell decline. Our study is unable to look at differences between PI vs. RTI-based cART
as NNRTI-based regimens were excluded. Given the known lower barrier to resistance in
NNRTI-based regimens and the possibility of rapid accumulation of resistance in the setting
of continued nonadherence, we did not feel that it was ethical to randomize participants to
continue NNRTI-based regimens in setting of continued nonadherence.
During our study, participants in the continuing cART arm had declines in their viral
loads, while those in the 3TC/FTC arm had increases in their viral loads, though the difference
between arms was not statistically significant. It is possible that participation in a clinical trial
with close monitoring, frequent interactions, and incentives may have resulted in greater
adherence over the study period. Indeed fewer participants in both arms reported missed
doses at the end of the study compared to baseline, suggesting that the frequent visits and/or
other study interventions with the site’s ongoing adherence work led to improvements in
adherence even in these patients with a history of persistently poor adherence. Although there
was no difference between the two arms in terms of adherence, it is possible that improved,
though suboptimal adherence to a potentially more active regimen in the cART arm would
result in better viral load responses[33].
Data from observational pediatric studies of 3TC/FTC monotherapy[19] have supported
3TC/FTC monotherapy as a strategy that can be used to bridge patients during periods of non-
adherence[21, 22]. Country level guidelines, including those in South Africa and previously,
the U.S., listed this strategy as one that could be employed[34, 35]. Based partly on the findings
from P1094 which were presented in abstract form at the 2014 Pediatric Virology Meeting in
Melbourne, Australia, the U.S. Department of Health and Human Services’ Guidelines, classi-
fied NRTI monotherapy regimens, including 3TC/FTC, as “not recommended as a treatment
strategy for children failing non-suppressive ART”[36]. In other countries, particularly settings
with limited antiretroviral options, such as South Africa, this strategy continues to be used
although clinicians do have limited access to third line drugs[34] [21, 22].
The study findings are specific to 3TC/FTC monotherapy, and are not meant to be extrapo-
lated to other monotherapy bridging or simplification strategies. There have been studies of
other monotherapy strategies (e.g., PI monotherapy with lopinavir/ritonavir, darunavir/rito-
navir, or atazanavir/ritonavir) that have demonstrated the ability to maintain immunologic
integrity, however, these strategies have been employed in the setting of virologic suppression
or simplification of multi-agent ART with simplification[37]. This study was not designed to
compare 3TC/FTC monotherapy to other simplified strategies and therefore cannot provide
evidence for how 3TC/FTC monotherapy would compare to those strategies.
The P1094 study has several important strengths. Specifically, it was a randomized con-
trolled study conducted through a highly experienced network, with standardized comprehen-
sive measurements, including immunology and immune activation. Further, the participants
were from multiple sites in the U.S., South America, and Thailand. The participants had a
wide range of CD4+ T cell counts and were failing on contemporary antiretroviral treatment
regimens. The study findings must be interpreted with some important study limitations in
mind. First, the early closure due to slow accrual resulted in a small sample size, leaving the
study under-powered to make certain comparisons and conclusions. Further, ARV drug expo-
sure (e.g., drug levels) were not collected to corroborate self-reported adherence. A relatively
healthy population participated with median initial CD4+ T cell counts > 500 cells/mm3,
therefore, we cannot generalize to those with lower baseline CD4+ T cell counts. However,
one would anticipate, as was seen in the Castagna study[16], that such a strategy would be
even more deleterious in that population with less CD4+ T cell reserve. Limited conclusions
can be drawn regarding immune activation and inflammation as a limited proportion of the
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participants had available data. Due to the early closure, we do not have resistance data. As
some clinicians may choose 3TC/FTC monotherapy with its decreased risk of accumulating
resistance as a strategy for managing youth with adherence difficulties, the lack of resistance
data limits our ability to analyze for differential acquisition of resistance mutations between
the two study arms. Lastly, the participants in the study may not be representative of all PHIV
youth and therefore our study findings may not be generalizable to all populations of PHIV
children and youth.
The findings of this first randomized controlled trial to evaluate 3TC/FTC monotherapy vs.
continuing failing cART, do not support the use of 3TC/FTC monotherapy as a strategy to
address nonadherence in patients failing cART, particularly in settings such as the U.S., where
there are other options available, even in the setting of drug resistance. Clinicians will need to
continue to assess the specific barriers and options for their young patients who are failing
cART and struggling with adherence in order to make the best care decisions with and for
their patients; the poor immunologic outcomes observed with 3TC/FTC monotherapy should
be factored into those decisions. In all settings, the focus needs to be on increasing the avail-
ability of ARV regimens that have high barriers to resistance, low pill burden, and are available
in suitable formulations and durably sustainable delivery mechanisms for youth. High priori-
ties include fixed dose combination formulations for second and third line regimens, long-act-
ing, injectable, and other novel cART delivery systems, as well as innovative ways of delivering
care and enhancing adherence, particularly for youth, given their challenges with medication
adherence.
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